Navigation Links
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:4/8/2008

he improvements were achieved without any limiting next day cognitive effects. In both the Phase 1 program and the Phase 2a trial, APD125 was well tolerated at all doses investigated.

About APD125

Discovered by Arena, APD125 is a novel and oral selective inverse agonist of the 5-HT2A serotonin receptor. The vast majority of approved drugs for insomnia activate the GABA-A receptor complex in the brain, causing a general suppressive effect on the central nervous system, or CNS. These GABAergic drugs are generally associated with CNS side effects, including a sensation of dullness and lethargy upon awakening, often referred to as the "hangover effect." Other potential problems associated with the GABAergic drugs include the risk of developing tolerance and drug dependency in at-risk populations. In addition, GABAergic drugs are scheduled controlled substances by the Drug Enforcement Administration due to their potential for abuse.

By selectively targeting the 5-HT2A receptor, APD125 acts through a different mechanism than currently marketed insomnia drugs and blocks one of several CNS activating pathways. Because of the different mechanism of action, APD125 may not have the side effects or abuse potential generally associated with currently approved GABAergic drugs. Through its novel mechanism, APD125 has the potential to reduce insomnia symptoms by improving sleep maintenance.

About Insomnia

Insomnia is characterized by inadequate or poor sleep due to nonrefreshing sleep, frequent wakening with difficulty falling back to sleep, difficulty falling asleep or waking too early. Most insomnia complaints relate to sleep maintenance issues, such as waking frequently or awakening too early, as opposed to problems with sleep latency (i.e. falling asleep). About 30% of US adults report some level of insomnia in the course of a year, and about 10% of US adults indicate that their condition is chronic. In these cases, the lack of restful sleep i
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  VentiRx Pharmaceuticals, Inc., a clinical stage ... commercialization of novel Toll-like receptor 8 (TLR8) ... and clinical activities at the company including ... clinical trials and future clinical development efforts. ... Officer Robert Hershberg , M.D., Ph.D. ...
(Date:9/2/2014)... Sept. 2, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... products marketed as XIAFLEX ® in the U.S. and ... President, Tom Wegman , will present at the following ... Rodman & Renshaw 16 th Annual ... Tuesday, September 9, 2014 at 9:10 a.m. EDT ...
(Date:9/2/2014)... OAKS, Calif. , Sept. 2, 2014 ... today announced the submission of a Marketing ... Agency (EMA) via the centralized procedure for ... of adults with melanoma that is regionally ... oncolytic immunotherapy administered as an intralesional injection ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6
(Date:9/2/2014)... York (PRWEB) September 02, 2014 - ... defined as a class of diagnostic test that analyzes ... The nucleic acids and proteins that belong to individual ... therapy, health condition, or risk of developing a specific ... better known as (MDx) evaluating the new class of ...
(Date:9/2/2014)... A New York City based company ... simple, yet revolutionary, product that will have ... health care costs for Americans. , REMIND-A-CAP™ ... puts control in the user's hands. It's a simple ... next date of intake by simply turning a knob. ...
(Date:9/2/2014)... may help scientists learn why patients with cystic fibrosis ... their lungs are relatively healthy. , The researchers ... treat pulmonary hypertension and Viagra for erectile dysfunction ... help them identify the root of the blood vessel ... , "We want to understand why these patients have ...
(Date:9/2/2014)... there might be a new salve to dominate medicine cabinets ... lowly salamander. Salamanders may not be the cuddliest of animals, ... of seriously damaged body parts. Now, a new report published ... Journal , identifies a small protein (called a "peptide") ... to unlocking the secret of this amazing wound healing trick ...
(Date:9/2/2014)... of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased ... Fellowship. This two-year fellowship, founded in 2008 by the ... Kanji Torizuka, MD, PhD, is designed to provide extensive ... and molecular imaging for Japanese physicians in the early ... proud to sponsor the Wagner-Torizuka Fellowship. This program honors ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 2Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 3Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 4Health News:REMIND-A-CAP™ , A New York City Based Company Invents Groundbreaking Prescription Cap to Curb Non-Adherence 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:Salamander skin peptide promotes quick and effective wound healing in mice 2Health News:SNMMI 2014-2016 Wagner-Torizuka Fellowship recipients announced 2
... moms have lower rates of depression than their stay-at-home counterparts, ... at greater risk for depression, suggests new research to be ... Association. The study shows that working mothers who ... be blended with relative ease showed higher levels of depression ...
... Paper money worldwide is contaminated with the potentially toxic chemical ... is used to make some plastics and consumer products such ... that BPA is an endocrine disruptor, which means that it ... to a number of health problems. Researchers analyzed 156 ...
... Aug. 19 (HealthDay News) -- Some patients do dream while ... still have a form of consciousness about themselves and the ... electroencephalography (EEG) to compare the structure of sleep in 11 ... five in a vegetative state (unresponsive wakefulness). "We used ...
... can reduce the risk of strokes as well as heart ... System neurologists caution that statins may not be appropriate for ... The article, by Dr. Murray Flaster and colleagues, appears in ... Neurotherapeutics . , A landmark 2006 study known as SPARCL, ...
... , THURSDAY, Aug. 18 (HealthDay News) -- A calcium ... to provide insight into the likelihood that certain patients at ... or stroke, researchers say. The test to detect ... take cholesterol-lowering drugs to reduce their cardiovascular risks, the study ...
... For better or for worse, in sickness and in ... associates marriage with reducing unhealthy habits such as smoking, ... However, new research is emerging that suggests married straight ... intimate relationships may pick up each other,s unhealthy habits ...
Cached Medicine News:Health News:Less depression for working moms who expect that they 'can't do it all' 2Health News:Paper Money Worldwide Tainted With BPA: Study 2Health News:People Appear to Dream While in Minimally Conscious State 2Health News:Cholesterial drugs can reduce the risk of stroke, but aren't for everyone 2Health News:Test for Calcium Buildup May Spot Heart Attack, Stroke Risk 2Health News:Long-term, intimate partnerships can promote unhealthy habits 2Health News:Long-term, intimate partnerships can promote unhealthy habits 3
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
... A histological embedment block ... This file system incorporates ... embedment block protection, simplified ... error and facilitation of ...
... The first instrumentation ... efficiently manage the ... Proven technology automatically ... collates cassettes sequentially. ...
Medicine Products: